Drugs / MILs™ - NSCLC
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04069936 | Oct 2019 → Oct 2021 | non-small cell lung carcinoma | WindMIL Therapeutics | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MILs - NSCLC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04069936 ↗ |
| Known as | Marrow Infiltrating Lymphocytes | “This study will examine the safety and efficacy of Marrow Infiltrating Lymphocytes-Non-Small Cell Lung Cancer (MILs™ - NSCLC) combined with nivolumab with or without tadalafil...” NCT04069936 ↗ |
| Modality | Cell therapy | “MILs™ - NSCLC are an adoptive cell therapy product derived via the activation and expansion of bone marrow T cells.” NCT04069936 ↗ |